The AirJector® CO2 therapeutic treatment achieves its physiological effects by taking advantage of a natural process known as the Bohr Effect. This process was first noted by Christian Bohr (the father of Nobel laureate Niels Bohr) in 1904. The effect stems from the fact that the oxygen-binding affinity of hemoglobin is inversely proportional to its pH and concentration of carbon dioxide. In practice, this means that if the carbon dioxide concentration increases somewhere in the body, pH decreases, and the hemoglobin molecule will bind to oxygen with lower affinity. Therefore, a larger amount of excess oxygen is released to the area concerned. Conversely, a decrease in carbon dioxide concentration provokes an increase in pH, which results in hemoglobin picking up more oxygen.
This natural mechanism fosters a wide range of physiological effects such as vasodilatation, which allows freer flow of blood and, thus, more efficient metabolism. Vasodilatation is also responsible for reduced blood pressure and heart rate.
AirJector® takes advantage of this effect by inducing a high CO2 condition immediately to the treated area. As the gas delivered by the AirCover® is absorbed by the skin, the blood vessels dilate, ensuring intensive metabolism and cellular respiration in the treated area.
PRIMARY INDICATIONS OF THE BOHR EFFECT INDUCED BY CO2 THERAPY
- Peripheral circulatory disorders, including arterial occlusive disease Stage I and Stage II
- Peripheral vascular disease (PVD)
- Extremity ischemia and chronic dermatological wounds
- Skin disorders and remediation of scars
- Pain management
- Skin laxity, elasticity, and hydration